Skip to content

Application of Triple Prescription Prescription for Blood Tumor Patients

Application of Triple Prescription Prescription for Blood Tumor Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105061
Enrollment
Unknown
Registered
2025-06-27
Start date
2023-03-20
Completion date
Unknown
Last updated
2025-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

leukemia

Interventions

Intervention group:The intervention group implemented a guideline based triple pre health compound plan. Use a self-made flowchart to conduct nutritional, physical, and psychological evaluations of th
control group:Routine care measures. Provide routine diet, exercise, and psychological intervention to patients.

Sponsors

Wuxi Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: (1) First diagnosis as a hematological tumor; (2) age>=18; (3) Informed consent for voluntary participation in this study; (4) There is no history of other systemic malignant tumors in the past; (5) Has not received any other anti-tumor treatments in the past or during the treatment process, such as radiotherapy, anti angiogenic therapy, immunotherapy, etc; (6) Able to walk independently; Exercise is permitted after medical evaluation by a physician.

Exclusion criteria

Exclusion criteria: Exclusion criteria: (1) unclear consciousness and language communication barriers; (2) Individuals with mental disorders; (3) Those who voluntarily withdraw for various reasons.

Design outcomes

Primary

MeasureTime frame
Exercise ability: 6 minutes walking distance;Nutritional indicators: Patient-generated Subjective Global Assessment;Psychological indicators: Anxiety and Depression Index;Exercise ability: Cancer fatigue scale;

Secondary

MeasureTime frame
Complications during chemotherapy: oral infection, perianal infection, respiratory infection, gastrointestinal reactions, skin and mucosal bleeding;

Countries

China

Contacts

Public ContactJun Xie

Wuxi Children's Hospital

xiejun@jiangnan.edu.cn+86 189 2152 3099

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 10, 2026